Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024

In 2024, the life science (LS) industry’s focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology.

The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.